Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of acute myeloid leukemia (AML), either M4 or M5 subtype de novo or resulting from a transformation from MDS or a myeloproliferative disorder.~* Patients with AML who (a) have failed primary therapy -defined as failing two induction chemotherapies, (b) have relapsed or (c) are not suitable for intensive induction chemotherapy will be eligible. OR~* Patients with AML blast crisis from CML if they are not suitable candidates for intensive induction chemotherapy or have failed imatinib mesylate OR~* Patients with secondary AML after MDS if they are not suitable candidates for intensive induction chemotherapy.~* ECOG 0,1,2, or 3~* Life expectancy \> 12 weeks.~* Adequate renal and hepatic function~Exclusion Criteria:~* Uncontrolled central nervous system involvement by AML~* Active cardiovascular disease as defined by NYHA class III-IV categorization.~* Intercurrent illness or medical condition precluding safe administration of ribavirin.~* Received any previous therapy within 28 days prior to study entry.Hydrea is permitted but must be stopped 7 days prior to starting study drug.~* Known infection with HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).